BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 23796280)

  • 1. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.
    Matza LS; Patrick DL; Riley AW; Alexander JJ; Rajmil L; Pleil AM; Bullinger M
    Value Health; 2013 Jun; 16(4):461-79. PubMed ID: 23796280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of electronic systems to collect patient-reported outcome (PRO) data-recommendations for clinical trial teams: report of the ISPOR ePRO systems validation good research practices task force.
    Zbrozek A; Hebert J; Gogates G; Thorell R; Dell C; Molsen E; Craig G; Grice K; Kern S; Hines S
    Value Health; 2013 Jun; 16(4):480-9. PubMed ID: 23796281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRO data collection in clinical trials using mixed modes: report of the ISPOR PRO mixed modes good research practices task force.
    Eremenco S; Coons SJ; Paty J; Coyne K; Bennett AV; McEntegart D;
    Value Health; 2014 Jul; 17(5):501-16. PubMed ID: 25128043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report.
    Rothman M; Burke L; Erickson P; Leidy NK; Patrick DL; Petrie CD
    Value Health; 2009; 12(8):1075-83. PubMed ID: 19804437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.
    Acquadro C; Berzon R; Dubois D; Leidy NK; Marquis P; Revicki D; Rothman M;
    Value Health; 2003; 6(5):522-31. PubMed ID: 14627058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the quality of healthcare provided to children.
    Mangione-Smith R; McGlynn EA
    Health Serv Res; 1998 Oct; 33(4 Pt 2):1059-90. PubMed ID: 9776949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Liaison Committee on Resuscitation (ILCOR) consensus on science with treatment recommendations for pediatric and neonatal patients: pediatric basic and advanced life support.
    International Liaison Committee on Resuscitation
    Pediatrics; 2006 May; 117(5):e955-77. PubMed ID: 16618790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The patient-reported outcome (PRO) consortium: filling measurement gaps for PRO end points to support labeling claims.
    Coons SJ; Kothari S; Monz BU; Burke LB
    Clin Pharmacol Ther; 2011 Nov; 90(5):743-8. PubMed ID: 21993428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
    Berger ML; Mamdani M; Atkins D; Johnson ML
    Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
    Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
    Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010.
    DeMuro C; Clark M; Mordin M; Fehnel S; Copley-Merriman C; Gnanasakthy A
    Value Health; 2012 May; 15(3):443-8. PubMed ID: 22583454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multinational trials-recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force report.
    Wild D; Eremenco S; Mear I; Martin M; Houchin C; Gawlicki M; Hareendran A; Wiklund I; Chong LY; von Maltzahn R; Cohen L; Molsen E
    Value Health; 2009 Jun; 12(4):430-40. PubMed ID: 19138309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.